Please assess the completion status of the following clinical trial:

Trial Title: Early HIV Therapy in Patients With High CD4 Cell Counts

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infection diagnosed by a rapid HIV test or any licensed ELISA test kit and documented in the participant's medical chart and re-verified at the time of study screening (hereafter: screen date).~* Most recent CD4+ cell count ≥ 250 cells/uL:~Arm A: CD4+ cell count 250-350 cells/uL Arm B: CD4+ cell count \>350 cells/uL~* Age ≥ 18 years.~* Residence within a 30 kilometer radius of the Bwizibwera HC-IV.~* Willing to initiate ART if the CD4+ cell count is ≥ 350 cells/uL.~* The following laboratory values obtained at the screening visit:~  * Absolute neutrophil count (ANC) ≥ 500 cells/uL~ * Hemoglobin ≥ 7.0 g/dL~ * Platelet count ≥ 50,000/uL~ * ALT (SGPT) ≤ 5 times greater than the upper limit of normal~ * Estimated glomerular filtration rate (eGFR) of ≥ 60 mL/minute by the Modification of Diet in Renal Disease (MDRD) formula:~eGFR = 186 \* Serum creatinine-1.154 \* Age-0.203 \* \[1.21 if African\] \* \[0.742 if female\]~* Ability to swallow oral medications.~* Ability and willingness of participant to give informed written consent.~Exclusion Criteria:~* Receipt at any time prior to study entry of \> 7 days cumulative treatment with any ARV or combination of ARVs, except ARVs taken for any length of time during pregnancy for the prevention of mother to child transmission (pMTCT) or ARVs taken for occupational exposure.~* For Arm B participants only: allergy/sensitivity to TDF, FTC, EFV, RTV, LPV or formulations of any of these three medications, or to co-formulated Truvada®.~* Active World Health Organization (WHO) HIV stage 3 or 4 illness~* Pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): Treatment for HIV in participants with CD4+ cell counts 250-350 cells/uL
- Arm B (Type: ACTIVE_COMPARATOR): Treatment for HIV in participants with CD4+ cell counts \>350 cells/uL

Based on this trial design, predict the completion outcome and termination type (if applicable).